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Abstract
Introduction: There is limited data on the experience with 
insertable cardiac monitors (ICMs) in patients with Brugada 
syndrome. Objective: To evaluate the outcome of ICM in 
symptomatic patients with Brugada syndrome who are at 
suspected low risk of sudden cardiac death (SCD). Methods: 
We conducted a prospective single-center cohort study in-
cluding all symptomatic patients with Brugada syndrome 
who received an ICM (Reveal LINQ) between July 2014 and 
October 2019. The main indication for monitoring was to ex-
clude ventricular arrhythmias as the cause of symptoms and 
to establish a symptom-rhythm relationship. Results: A total 
of 20 patients (mean age, 39 ± 12 years; 55% male) received 
an ICM during the study period. Nine patients (45%) had a 
history of syncope (presumed nonarrhythmogenic), and 5 
patients had a recent syncope (< 6 months). During a median 
follow-up of 32 months (interquartile range, 11–36 months), 
3 patients (15%) experienced an episode of nonsustained 
ventricular arrhythmia. No patient died suddenly or experi-
enced a sustained ventricular arrhythmia, and no patient 
had a recurrence of syncope. Overall, 17 patients (85%) ex-
perienced symptoms during follow-up, of whom 10 patients 
had an ICM-detected arrhythmia. In 4 patients (20%), the 
ICM-detected arrhythmia was an actionable event. ICM-
guided management included antiarrhythmic drug therapy 
for symptomatic ectopic beats (n = 3), pulmonary vein isola-
tion, and oral anticoagulation for atrial fibrillation (n = 1), 
electrophysiological study for risk stratification (n = 1), and 
pacemaker implantation for atrioventricular block (n = 1). 
Conclusions: An ICM can be used to exclude ventricular ar-
rhythmias in symptomatic patients with Brugada syndrome 
at low risk of SCD. Furthermore, an ICM-detected arrhythmia 
changed clinical management in 20% of patients.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Risk stratification in patients with Brugada syndrome 
is challenging [1–3]. Several risk factors for arrhythmic 
events (sustained ventricular arrhythmia or sudden car-
diac death [SCD]) have been identified, but the most ro-
bust predictors are a spontaneous type 1 Brugada electro-
cardiogram (ECG) pattern and presumed arrhythmogen-
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ic syncope [1–3]. There is controversy over the predictive 
role of inducible sustained ventricular arrhythmia during 
electrophysiological study (EPS), but it seems to be infor-
mative for predicting arrhythmic risk in moderate-risk 
patients when using less aggressive stimulation protocols 
(up to double extrastimuli) [1–5].
The current guidelines recommend an implantable 
cardioverter-defibrillator (ICD) in patients with Brugada 
syndrome with aborted cardiac arrest, documented spon-
taneous sustained ventricular arrhythmias, or a combina-
tion of spontaneous type 1 Brugada ECG pattern and a 
history of syncope [6, 7]. The downside of ICD therapy is 
the risk of late complications, inappropriate ICD shocks, 
and psychological burden [8].
In clinical practice, physicians are confronted with pa-
tients with Brugada syndrome who have symptoms such 
as palpitations, near-syncope, or nonarrhythmic syncope 
[5, 9]. Some symptoms are caused by anxiety for arrhyth-
mic events, but it may be difficult to differentiate this 
from clinically relevant arrhythmias. Insertable cardiac 
monitors (ICM) are increasingly being used in doubtful 
cases to exclude ventricular arrhythmias as the cause of 
symptoms [5, 10, 11]. The recent ESC guidelines and ex-
pert consensus conference report support the use of ICMs 
in patients with Brugada syndrome and recurrent unex-
plained syncope [12, 13]. The aim of the present study is 
to evaluate the use of ICMs in symptomatic patients with 
Brugada syndrome who are presumed to be at low risk of 
SCD.
Methods
Study Design and Population
The present study is a prospective single-center cohort study 
which included all symptomatic adults with Brugada syndrome 
who received an ICM between July 2014 and October 2019. The 
main indication for arrhythmia monitoring was to exclude ven-
tricular arrhythmias as the cause of symptoms. Most patients have 
received a 24-h Holter monitoring prior to ICM implantation. Pa-
tients with high risk features, such as a spontaneous sustained ven-
tricular arrhythmia, a combination of spontaneous type 1 Brugada 
ECG pattern and arrhythmic syncope, or positive EPS, were not 
considered for an ICM but were recommended an ICD [6, 14]. 
Until 2014, we recommended EPS to all patients with spontaneous 
or drug-induced Brugada ECG pattern. Thereafter, EPS was only 
proposed to doubtful cases. The study was approved by the insti-
tutional review board of the Erasmus MC.
Device Programming and Follow-Up
All ICMs (Reveal LINQ, Medtronic) were implanted subcutane-
ously using the incision and insertion tool. Furthermore, all patients 
received a handheld activator to indicate their symptoms when nec-
essary. The ICM was programmed according to local settings: tachy-
cardia detection was set to 176 bpm for 16 beats (nominal setting); 
bradycardia setting to 30 bpm for 8 beats (nominal 4 beats); pause 
setting to 4.5 s (nominal 3.0 s); and atrial fibrillation (AF) setting to 
“AF only.” These settings were chosen to improve the signal-to-noise 
ratio. All devices were connected to the CareLink network (Medtron-
ic) for remote monitoring. Patients were discharged on the same day 
of implantation. Ten days after implantation, the patients were seen 
at the outpatient clinic to check their wound and to interrogate the 
ICM. Afterwards, the patients were seen regularly at the outpatient 
clinic according to routine patient care. ICM checkups were per-
formed at the outpatient clinic every 6 months or earlier when neces-
Table 1. Clinical baseline characteristics 
Total group
(n = 20)
Age, years 39±12
Gender, male 11 (55)
Family history of SCD in first-degree relatives 8 (40)
History of atrial flutter at age <35 years 1 (5)
Symptoms
Palpitations 11 (55) 
Syncope 9 (45)
Near syncope 4 (20)
Systemic systolic ventricular function
Normal left ventricular ejection fraction (≥55%) 20 (100)
Genetic variance
No (likely) pathogenic SCN5A variant 14 (70)
No genetic testing 4 (20)
Pathogenic SCN5A variant 2 (10)
Clinical presentation
Ajmaline induced Brugada ECG 14 (70)
Fever induced Brugada ECG 4 (20)
Spontaneous Brugada ECG 2 (10)
Electrocardiography
Sinus rhythm 20 (100)
PR interval, ms 169±28
QRS duration, ms 103±18
QTc duration, ms 391±22
Fragmented QRS 4 (20)
EP study 7 (35)
No inducible sustained VA 7 (35)
VERP <200 ms 2 (10)
Holter monitoring 16 (80)
No PVCs 10 (50)
≤1% PVCs 6 (30)
Supraventricular tachycardia 0
Ventricular tachycardia 0
SA-ECG 16 (80)
Late potentials 10 (50)
Data are presented as n (%) or mean ± standard deviation. 
ECG, electrocardiogram; EP, electrophysiological; PVC, premature 
ventricular arrhythmia; SCD, sudden cardiac death; VA, ventricular 
arrhythmia; VERP, ventricular effective refractory period.
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sary based on symptoms or transmitted episodes. Remote monitor-
ing was performed on a daily basis during weekdays. Remote moni-
toring involves automatic unscheduled transmission of alert events.
Classification of Episodes and Endpoints
All patient-activated episodes and automatically detected epi-
sodes were classified. In the case of an inappropriate automati-
cally detected episode, the cause of inappropriate detection was 
specified, if possible. A regular broad complex tachycardia (BCT) 
was considered a ventricular arrhythmia if there was a sudden on-
set and a change in the QRS morphology in comparison to the 
baseline rhythm. An irregular BCT was considered a ventricular 
arrhythmia if there was a sudden onset and a polymorphic QRS 
morphology. A regular broad or small complex tachycardia was 
considered a supraventricular tachycardia if there was a sudden 
onset and no change in QRS morphology. In the case of doubt, a 
second electrophysiologist was consulted for the final diagnosis. 
Finally, it was established whether a detected arrhythmia resulted 
in a change in patient management (“actionable event”).
Statistical Analysis
Data are presented as mean ± standard deviation or as median 
with corresponding 25th and 75th percentile, as appropriate. Cat-
egorical variables are presented as frequencies and percentages. 
Statistical analyses were performed using SPSS version 21.
Results
Study Population
A total of 20 patients with Brugada syndrome (mean 
age 39 ± 12 years; 55% male) received an ICM during the 
study period. Baseline characteristics of the study popula-
tion are listed in Tables 1 and 2. Symptoms before ICM 
implantation consisted of syncope suggestive of a nonar-
rhythmogenic cause (n = 9, 45%), palpitations (n = 7, 
Table 2. Detailed overview of baseline characteristics and clinical outcomes
Age at diagnosis, 
years, and gender
Type of 
Brugada 
Symptoms before 
ICM
SCD 
first-degree 
relatives
SCD 
<35 years 
first-degree 
relatives
Proband 
status
SND History of 
inducible 
VA
SCN5A 
variant
Symptoms during 
follow-up
ICM-detected 
rhythm
Management
20, M Ajmaline Syncope – – + – NA NA Symptoms (not specified) SR –
22, M Ajmaline Syncope + + – – NA – Asymptomatic – –
23, M Ajmaline Near-syncope, 
palpitations
– – + – NA – Near-syncope, palpitations PAC/PVC, SVT, 
NSVT
AAD, EPS
24, F Ajmaline Near-syncope, 
palpitations
+ – – – – NA Asymptomatic – –
29, M Ajmaline Palpitations – – – – – – Asymptomatic ST, SB –
30, F Ajmaline Palpitations + – + – NA – Symptoms (not specified) SR –
35, M Ajmaline Palpitations – – + – – – Palpitations, 
amaurosis fugax
PAC, AF AAD, NOAC, 
PVI
37, M Ajmaline Syncope + + + – – – Palpitations PAC –
41, M Ajmaline Syncope + – + – NA – Palpitations PVC –
41, F Ajmaline Near-syncope, 
palpitations
+ + + – NA NA Palpitations SR –
41, F Ajmaline Syncope + – + – NA – Palpitations PVC, NSVT –
43, M Ajmaline Syncope + + – – – + Palpitations SA –
44, F Ajmaline Near-syncope, 
palpitations
– – – – – – Palpitations PVC –
55, F Ajmaline Syncope – – + – NA – Symptoms (not specified) SR –
25, F Fever Palpitations – – – – NA + Near-syncope, palpitations PAC/PVC, SA –
39, M Fever Syncope – – – – NA – Symptoms (not specified) SR –
42, M Fever Palpitations – – + – – – Palpitations PAC/PVC, NSVT AAD
50, F Fever Syncope – – + + NA – Near-syncope, palpitations PAC, SVT, AVB, SA PM
53, F Spontaneous Palpitations – – + – NA – Symptoms (not specified) SR –
63, M Spontaneous Palpitations – – + – NA NA Palpitations SR –
Patients are sorted on age at diagnosis and type of Brugada syndrome. AAD, antiarrhythmic drug therapy; AF, atrial fibrillation; AVB, atrioventricular block; ICM, insertable cardiac monitor; NA, not available; 
NSVT, nonsustained ventricular tachycardia; PAC, premature atrial complexes; PM, pacemaker; PVC, premature ventricular complexes; SA, sinus arrest; SB, sinus bradycardia; SCD, sudden cardiac death; SND, 
sinus node disease; SR, sinus rhythm; ST, sinus tachycardia; SVT, supraventricular tachycardia; VA, ventricular arrhythmia. +, present; –, absent.
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35%), or a combination of near-syncope and palpitations 
(n = 4, 20%). Of the 9 patients with syncope, 7 patients 
(78%) had only 1 syncopal event, and 5 patients (56%) 
had a recent syncope (< 6 months before ICM implanta-
tion). A detailed patient-level description of patient char-
acteristics is presented in Table 2. There were no ICM- or 
procedure-related complications.
ICM-Detected Episodes
During a median follow-up of 32 months (IQR, 11–36 
months), a total of 1,912 episodes were transmitted to the 
CareLink network system (Appendix). There were 904 
(47%) patient-activated episodes and 1,008 (53%) auto-
matically detected episodes. The majority of patient-acti-
vated episodes (98%) comprised sinus rhythm with or 
without ectopy; thus, only a minority of patient-activated 
episodes comprised a significant arrhythmia.
Detection of Ventricular Arrhythmia Episodes
During follow-up, 3 patients (15%) experienced an ep-
isode of nonsustained ventricular arrhythmia (Table 2; 
Fig. 1).
The first patient was a 23-year-old male with ajma-
line-induced Brugada syndrome and an anxiety disor-
Symptomatic patients with Brugada
syndrome and an ICM (n = 20) 
Asymptomatic 
patients (n = 2)
No ICM-detected
arrhythmia during FU
(n = 9)
Symptomatic 
ICM-detected
arrhythmia (n = 10)
Asymptomatic 
ICM-detected
arrhythmia (n = 1)
ICM-detected
arrhythmia during FU
(n = 11)
Diagnostic
yield
Sinus bradycardia
(n = 1)
Conservative
(n = 1)
Conservative 
(n = 6)
AAD (n = 3)
Conservative 
(n = 2)
Conservative 
(n = 1)
EP study (n = 1)
AAD (n = 2)
Conservative 
(n = 2)
Pacemaker
 (n = 1)
Symptomatic
PVCs/PACs 
(n = 9)
NSVT
(n = 3)
SVT 
(n = 2)
Sinus arrest 
(n = 3)
AV block 
(n = 1)
AF 
(n = 1)
NOAC (n = 1)
AAD (n = 1)
PVI (n = 1) 
Symptomatic 
patients (n = 7)
Fig. 1. Overview of insertable cardiac monitor (ICM)-detected arrhythmias and the therapeutic management. 
One patient had both sinus arrest and atrioventricular (AV) block and required a pacemaker. AAD, anti-arrhyth-
mic drug; AF, atrial fibrillation; EP, electrophysiological; NSVT, nonsustained ventricular tachycardia; PAC, 
premature atrial complex; PVC, premature ventricular complex; PVI, pulmonary vein isolation; SVT, supraven-
tricular tachycardia.
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der (treated by psychiatrist) who received an ICM due 
to recurrent unexplained symptoms (i.e., near-syncope 
and palpitations). During follow-up, he experienced 6 
episodes of symptomatic regular slow monomorphic 
nonsustained ventricular arrhythmia (4–8 beats, pa-
tient-activated). It is important to note that the major-
ity of the patient-activated episodes did not show any 
arrhythmia. The patient underwent an EPS which was 
negative, and based on the negative EPS, he was treated 
conservatively.
The second patient was a 41-year-old female with aj-
maline-induced Brugada syndrome and a positive family 
history of SCD who received an ICM for a history of pre-
sumed nonarrhythmogenic syncope. She experienced 
one symptomatic episode of irregular nonsustained ven-
tricular arrhythmia (9 beats, patient-activated) with pal-
pitations 5 months after ICM implantation. It was decid-
ed to continue arrhythmia monitoring and to perform an 
EPS if there was a recurrent ventricular arrhythmia epi-
sode.
The third patient was a 42-year-old male with fever-
induced Brugada syndrome, fragmented QRS, and a neg-
ative EPS who received an ICM for palpitations. He expe-
rienced a symptomatic regular monomorphic nonsus-
tained ventricular arrhythmia (7 beats, patient-activated) 
16 months after ICM implantation. Because he also had 
symptomatic ventricular ectopic beats, he was treated 
successfully with quinidine sulphate. No ventricular ar-
rhythmia was seen thereafter. His ICM was explanted 3.5 
years after implantation.
No patient died suddenly or experienced a sustained 
ventricular arrhythmia.
Symptom-Rhythm Correlation
No patient experienced syncope during a median fol-
low-up of 32 months (IQR, 11–36 months). Overall, 17 
patients (85%) experienced any symptom during follow-
up (Fig. 1; Table 2). Ten of 17 (59%) symptomatic patients 
had an ICM-detected arrhythmia. In 4 patients (20%), the 
ICM-detected arrhythmia was considered an actionable 
event. ICM-guided management included antiarrhyth-
mic drug therapy for symptomatic ectopic beats (n = 3), 
pulmonary vein isolation and oral anticoagulation for 
atrial fibrillation (n = 1), EPS for risk stratification (n = 
1), and pacemaker implantation for high-degree atrio-
ventricular block (n = 1).
Two patients with ventricular arrhythmia episodes 
and actionable events have been described previously. 
Furthermore, a 35-year-old male with ajmaline-induced 
Brugada syndrome experienced symptomatic paroxys-
mal AF detected by the ICM. He was started on oral an-
ticoagulation and sotalol. In addition, he was scheduled 
for a pulmonary vein isolation.
A 50-year-old female with recurrent syncope, fever-
induced Brugada syndrome and a positive family history 
of SCD at young age (third-degree relative) received a du-
al-chamber pacemaker after her ICM detected a 10 s 
pause due to high-degree AV block. During a follow-up 
of 18 months after pacemaker implantation, no episode 
of ventricular arrhythmia was documented by her pace-
maker.
Overall, in 10 patients (45%) the ICM was explanted. 
In 9 patients, the ICM was explanted due to end of battery 
life.
Discussion
The present study is one of the largest case series eval-
uating the outcome of continuous monitoring in adults 
with Brugada syndrome with low risk of SCD. During 
almost 3 years of follow-up, there was a low risk of non-
sustained ventricular arrhythmia and an absence of sus-
tained ventricular arrhythmia. In 4 patients (20%), an 
ICM-guided diagnosis resulted in a change of patient 
management. No patient required an ICD during follow-
up. Thus, an ICM may provide reassurance to a symp-
tomatic patient with Brugada syndrome.
Risk Stratification
Brugada syndrome is characterized by an increased 
risk of SCD. Several risk factors for SCD have been iden-
tified including, among others, spontaneous type 1 Bru-
gada ECG pattern, history of arrhythmogenic syncope, 
positive EPS, family history of SCD < 35 years, fraction-
ated QRS, early repolarization in the peripheral leads, in-
creased Tpeak–Tend interval, sinus node dysfunction, first-
degree AV block, and nonsustained ventricular arrhyth-
mia [1, 4]. The role of EPS in patients with Brugada 
syndrome is controversial. A recent meta-analysis dem-
onstrated that ventricular arrhythmia induction using 
single or double extrastimuli was associated with a 2- to 
3-fold increased risk of arrhythmic events [4]. However, 
it is important to note that a negative EPS alone is not suf-
ficient to preclude arrhythmia risk, especially in patients 
with clinical high-risk features. Using a recently devel-
oped risk score (published in 2017) based on clinical pa-
rameters, the risk score in our study population ranged 
from 0 to 3 points corresponding to an estimated 5-year 
event rate ranging from 1.6 to 16.6% [1]. The arrhythmic 
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event rate in our study population was 0% during a me-
dian follow-up of almost 3 years, supporting the clinical 
judgment not to implant a prophylactic ICD in our study 
population.
Role of ICM in Brugada Syndrome
An ICM is a sensitive tool to detect paroxysmal ar-
rhythmias and is particularly useful for establishing a 
symptom-rhythm correlation. In the general popula-
tion, there is a clear indication for an ICM in patients 
with recurrent unexplained syncope [12, 15]. Interest-
ingly, the recent ESC guidelines give a class IIa indica-
tion (level of evidence C) for an ICM (instead of an 
ICD) in Brugada patients with recurrent unexplained 
syncope who are at low risk of SCD [12]. Currently, 
there is limited published data on the use of ICM in pa-
tients with Brugada syndrome [5, 10, 11, 16–18]. A few 
case reports in Brugada patients with presumed nonar-
rhythmogenic syncope have demonstrated the detec-
tion of self-terminating sustained ventricular arrhyth-
mia by the ICM [16, 17]. These patients received a pro-
phylactic ICD. Until now, there are 2 reported case 
series with > 10 patients. In 2012, Kubala et al. [10] re-
ported a retrospective analysis of 11 patients (mean age 
44 years) with Brugada syndrome and ICM (Reveal DX, 
Medtronic). Most patients were symptomatic and had 
a previous EPS; furthermore, half of the study popula-
tion had a spontaneous type 1 Brugada ECG pattern. 
During a mean follow-up of 33 months, no ventricular 
arrhythmic event was documented in patients with re-
currence of symptoms. In 2017, Giustetto et al. [5] re-
ported the experience with ICMs in the Piedmont Bru-
gada registry. In this study, 13 patients with neurally 
mediated syncope and 14 patients with unexplained, 
suspected arrhythmia-related syncope received an 
ICM. During follow-up, no patient had an arrhythmic 
event (defined as ventricular fibrillation, sustained ven-
tricular arrhythmia, or SCD). Our study expands the 
experience with ICM in symptomatic patients with 
Brugada syndrome and is in line with previous studies 
by demonstrating no sustained ventricular arrhythmias 
during follow-up. In contrast to previous studies, we 
reported all ICM-detected arrhythmic events indepen-
dent of initial symptoms.
Considerations
There seems to be a role to use ICM in selected symp-
tomatic Brugada patients. Patients who are recently diag-
nosed with Brugada syndrome usually experience in-
creased anxiety considering the increased risk of SCD. 
The heightened awareness of palpitations or near-synco-
pe may be troublesome for patients, and in this respect an 
ICM with remote monitoring may provide reassurance 
by excluding clinically relevant arrhythmias during symp-
toms.
On the other hand, when using an ICM, there are some 
limiting factors which should be considered such as de-
vice costs, data overload, clinical relevance of device-de-
tected ventricular arrhythmia and medical overuse. The 
issue of data overload is highlighted by the recording of 
almost 2,000 episodes in 20 patients in our study popula-
tion. A dedicated telemonitoring staff with a proper in-
frastructure is advised before providing such a service to 
patients.
Study Limitations
Although this is one of the largest reported series 
on the use of ICM in Brugada patients, the sample size 
is still relatively small. This may impact on the external 
validity of the study results. Furthermore, a longer 
follow-up duration may potentially increase the likeli-
hood of detecting ventricular arrhythmias. However, 
the average battery life of the Reveal LINQ is 3 years. 
A longer follow-up would thus require replacement 
of the ICM. Finally, asymptomatic ventricular arrhyth-
mia episodes which are shorter (< 16 beats) or slower 
(< 176 bpm) than the programmed cutoff values will be 
missed. Therefore, the true incidence of ventricular ar-
rhythmia episodes will most likely be higher in this 
population.
Conclusion
An ICM can be used to exclude ventricular arrhyth-
mias in symptomatic patients with Brugada syndrome at 
presumed low risk of SCD, thereby providing reassur-
ance. Furthermore, an ICM-detected arrhythmia changed 
clinical management in 20% of patients.
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Appendix
Overview of ICM-Detected Arrhythmias
Total episodes
(n = 1,912)
Symptom episodes* 904 (47)
Sinus rhythm 888 (98)
without ectopy 411
with PVCs 255
with PACs 222
Regular broad complex tachycardia 8 (<1)
Regular small complex tachycardia 4 (<1)
Atrial fibrillation 4 (<1)
Brady episodes* 822 (43)
Sinus bradycardia 818 (99)
Sinus rhythm 2  
with undersensing of PVCs 2
Sinus arrest 2 (<1)
Tachycardia episodes* 121 (6)
Sinus rhythm 121 (100)
without ectopy 98
with oversensing 13
with noise 9
with PACs 1
Total episodes
(n = 1,912)
Pause episodes* 53 (3)
Sinus rhythm 48 (91)
with sudden drop of R-wave 41
with small R-waves 6
with undersensing of PVCs 1
Sinus arrest 4 (8)
AV-block 1 (2)
Atrial tachycardia* 11 (<1) 
Sinus rhythm 11 (100)
Atrial fibrillation* 1 (<1)
Sinus rhythm with PACs 1 (100)
Data are presented as n (%). * Episode classification by ICM. 
AV-block, atrioventricular block; PAC, premature atrial complex; 
PVC, premature ventricular complex; SA, sino-atrial.
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